Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
319 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Nasopharyngeal Cancer - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2017, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape. Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 13, 7 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 8, 2 and 5 molecules, respectively. Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Nasopharyngeal Cancer - Overview 7 Nasopharyngeal Cancer - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 Nasopharyngeal Cancer - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 20 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 27 Advenchen Laboratories LLC 27 Ambrx Inc 27 arGEN-X BV 28 Atara Biotherapeutics Inc 28 AVEO Pharmaceuticals Inc 29 BeiGene Ltd 29 BioDiem Ltd 30 Biomics Biotechnologies Co Ltd 30 Bristol-Myers Squibb Company 31 CBT Pharmaceuticals Inc 31 Celgene Corp 32 Cell Medica Ltd 32 F. Hoffmann-La Roche Ltd 33 GlaxoSmithKline Plc 33 Incyte Corp 34 Jiangsu Hengrui Medicine Co Ltd 35 MedImmune LLC 35 Merck & Co Inc 36 Merck KGaA 36 Millennium Pharmaceuticals Inc 37 Neonc Technologies Inc 37 Novartis AG 38 Ono Pharmaceutical Co Ltd 38 Otsuka Holdings Co Ltd 39 Systimmune Inc 39 Tessa Therapeutics Pte Ltd 40 Theravectys SA 40 Viracta Therapeutics Inc 41 Yabao Pharmaceutical Group Co Ltd 41 Nasopharyngeal Cancer - Drug Profiles 42 alisertib - Drug Profile 42 Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile 48 apatinib - Drug Profile 49 APG-1387 - Drug Profile 55 ARGX-110 - Drug Profile 56 ATA-129 - Drug Profile 61 atezolizumab - Drug Profile 64 avelumab - Drug Profile 84 azacitidine - Drug Profile 95 baltaleucel-T - Drug Profile 101 bevacizumab - Drug Profile 103 BGBA-317 - Drug Profile 115 CBT-501 - Drug Profile 118 Cellular Immunotherapy for EBV Associated Malignancies - Drug Profile 120 Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Cancer - Drug Profile 121 Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile 122 Cellular Immunotherapy for Oncology - Drug Profile 123 Cellular Immunotherapy for Oncology - Drug Profile 124 Cellular Immunotherapy for Oncology - Drug Profile 126 Cellular Immunotherapy for Oncology and Infectious Disease - Drug Profile 127 Cellular Immunotherapy to Target EPCAM for Oncology - Drug Profile 128 Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile 129 Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer - Drug Profile 130 DC-120 - Drug Profile 131 donafenib - Drug Profile 132 durvalumab + tremelimumab - Drug Profile 134 EBViNT - Drug Profile 140 Epstein-Barr virus vaccine - Drug Profile 141 ficlatuzumab - Drug Profile 142 GSK-2849330 - Drug Profile 146 INCB-62079 - Drug Profile 147 ipilimumab - Drug Profile 148 ipilimumab + nivolumab - Drug Profile 159 JS-001 - Drug Profile 167 MAK-683 - Drug Profile 169 Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile 170 Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 171 MVA vaccine - Drug Profile 172 NEO-212 - Drug Profile 173 nimotuzumab - Drug Profile 175 nivolumab - Drug Profile 180 OPB-111077 - Drug Profile 229 PDR-001 - Drug Profile 230 pembrolizumab - Drug Profile 233 SHR-1210 - Drug Profile 294 SIM-005A - Drug Profile 296 Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer - Drug Profile 297 SV-638 - Drug Profile 298 TT-10 - Drug Profile 299 Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 301 Vaccine for Oncology - Drug Profile 302 Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile 303 Vaccine to Target LMP-2 for Nasopharyngeal Carcinoma - Drug Profile 304 VRx-3996 - Drug Profile 305 Nasopharyngeal Cancer - Dormant Projects 307 Nasopharyngeal Cancer - Discontinued Products 308 Nasopharyngeal Cancer - Product Development Milestones 309 Featured News & Press Releases 309 Appendix 314 Methodology 314 Coverage 314 Secondary Research 314 Primary Research 314 Expert Panel Validation 314 Contact Us 314 Disclaimer 315
List of Tables
Number of Products under Development for Nasopharyngeal Cancer, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017 Nasopharyngeal Cancer - Pipeline by Ambrx Inc, H2 2017 Nasopharyngeal Cancer - Pipeline by arGEN-X BV, H2 2017 Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017 Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017 Nasopharyngeal Cancer - Pipeline by BeiGene Ltd, H2 2017 Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H2 2017 Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017 Nasopharyngeal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2017 Nasopharyngeal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017 Nasopharyngeal Cancer - Pipeline by Celgene Corp, H2 2017 Nasopharyngeal Cancer - Pipeline by Cell Medica Ltd, H2 2017 Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017 Nasopharyngeal Cancer - Pipeline by Incyte Corp, H2 2017 Nasopharyngeal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 Nasopharyngeal Cancer - Pipeline by MedImmune LLC, H2 2017 Nasopharyngeal Cancer - Pipeline by Merck & Co Inc, H2 2017 Nasopharyngeal Cancer - Pipeline by Merck KGaA, H2 2017 Nasopharyngeal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 Nasopharyngeal Cancer - Pipeline by Neonc Technologies Inc, H2 2017 Nasopharyngeal Cancer - Pipeline by Novartis AG, H2 2017 Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 Nasopharyngeal Cancer - Pipeline by Otsuka Holdings Co Ltd, H2 2017 Nasopharyngeal Cancer - Pipeline by Systimmune Inc, H2 2017 Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017 Nasopharyngeal Cancer - Pipeline by Theravectys SA, H2 2017 Nasopharyngeal Cancer - Pipeline by Viracta Therapeutics Inc, H2 2017 Nasopharyngeal Cancer - Pipeline by Yabao Pharmaceutical Group Co Ltd, H2 2017 Nasopharyngeal Cancer - Dormant Projects, H2 2017 Nasopharyngeal Cancer - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
